Our biomarkers can be used separately or in combination to reflect aberrant lung tissue remodeling, wound healing, and inflammation. The biomarkers have shown to be increased in progressive IPF patients and function as pharmacodynamic biomarkers.
Our tissue-derived Protein Fingerprint biomarkers can quantify structural tissue changes occurring in the lungs of patients with asthma. Our biomarkers are increased in asthmatic patients and are related to different subtypes.
Our tissue-derived Protein Fingerprint biomarkers can quantify structural tissue changes occurring in the lungs of patients with COPD. Our biomarkers are related to disease activity in COPD patients and are able to predict mortality.
Please don't hesitate to contact us if you have any questions or other inquiries.